"Neoadjuvant Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
| Descriptor ID |
D020360
|
| MeSH Number(s) |
E02.186.450
|
| Concept/Terms |
Neoadjuvant Therapy- Neoadjuvant Therapy
- Neoadjuvant Therapies
- Therapies, Neoadjuvant
- Therapy, Neoadjuvant
- Neoadjuvant Treatment
- Neoadjuvant Treatments
- Treatment, Neoadjuvant
- Treatments, Neoadjuvant
|
Below are MeSH descriptors whose meaning is more general than "Neoadjuvant Therapy".
Below are MeSH descriptors whose meaning is more specific than "Neoadjuvant Therapy".
This graph shows the total number of publications written about "Neoadjuvant Therapy" by people in this website by year, and whether "Neoadjuvant Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 4 | 5 |
| 1999 | 1 | 5 | 6 |
| 2000 | 5 | 9 | 14 |
| 2001 | 4 | 7 | 11 |
| 2002 | 4 | 7 | 11 |
| 2003 | 5 | 12 | 17 |
| 2004 | 14 | 17 | 31 |
| 2005 | 15 | 25 | 40 |
| 2006 | 19 | 23 | 42 |
| 2007 | 16 | 33 | 49 |
| 2008 | 16 | 38 | 54 |
| 2009 | 10 | 28 | 38 |
| 2010 | 14 | 37 | 51 |
| 2011 | 22 | 45 | 67 |
| 2012 | 34 | 38 | 72 |
| 2013 | 29 | 46 | 75 |
| 2014 | 36 | 29 | 65 |
| 2015 | 31 | 44 | 75 |
| 2016 | 22 | 53 | 75 |
| 2017 | 26 | 61 | 87 |
| 2018 | 38 | 54 | 92 |
| 2019 | 43 | 43 | 86 |
| 2020 | 39 | 63 | 102 |
| 2021 | 44 | 73 | 117 |
| 2022 | 24 | 69 | 93 |
| 2023 | 13 | 84 | 97 |
| 2024 | 2 | 13 | 15 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.
-
Are We Ready for Life in the Fast Lane? A Critical Review of Preoperative Hypofractionated Radiotherapy for Localized Soft Tissue Sarcoma. Semin Radiat Oncol. 2024 Apr; 34(2):180-194.
-
Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer. Oncotarget. 2024 Mar 19; 15:238-247.
-
Evaluation of traditional targeted axillary dissection eligibility criteria for node-positive breast cancer after neoadjuvant chemotherapy in a prospective multicenter registry. Eur J Surg Oncol. 2024 Apr; 50(4):108245.
-
Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study. Br J Surg. 2024 Mar 02; 111(3).
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
-
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.
-
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer. Eur J Cancer. 2024 Apr; 201:113920.
-
ASO Author Reflections: Neoadjuvant Systemic Therapy and Nodal Management in cT1-2 N0 Triple-Negative Breast Cancer. Ann Surg Oncol. 2024 May; 31(5):3196-3197.
-
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer. Breast Cancer Res. 2024 01 31; 26(1):20.
-
Multi-omics approaches for biomarker discovery in predicting the response of esophageal cancer to neoadjuvant therapy: A multidimensional perspective. Pharmacol Ther. 2024 Feb; 254:108591.